Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
| ▸ | CPA1 | P15085 | 3/20 | 0.45 |
| ▸ | CPA3 | P15088 | 3/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007628 | 0.86 | CYP1A2 (0.68) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL252900 | 0.86 | CYP1A2 (0.68) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL629350 | 0.86 | CYP1A2 (0.68) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL30543817 | 0.81 | CYP1A2 (0.56) | PTGS2CYP1A2GRIA2FOLH1CPA1 | |
| SCHEMBL14610943 | 0.79 | FOLH1 (0.43) | CYP1A2FOLH1CPA1CPA3CPB1 | |
| SCHEMBL6841478 | 0.78 | CYP1A2 (0.51) | PTGS2CYP1A2GRIA2FOLH1CPA1 | |
| SCHEMBL5870627 | 0.78 | CYP1A2 (0.51) | PTGS2CYP1A2GRIA2FOLH1CPA1 | |
| SCHEMBL9456007 | 0.77 | GRIA2 (0.57) | PTGS2CYP1A2GRIA2CPA1MME | |
| SCHEMBL9748537 | 0.76 | CYP2C19 (0.50) | CYP1A2CPA1CPA3CYP2C19 | |
| SCHEMBL20168741 | 0.76 | FOLH1 (0.59) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | PTGS2 1689/4885CYP1A2 3906/4885GRIA2 4451/4885 |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | PTGS2 943/4885CYP1A2 3441/4885GRIA2 4324/4885 |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | PTGS2 1529/4885CYP1A2 4095/4885GRIA2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.